Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14309MR)

This product GTTS-WQ14309MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ANGPT2&VEGFA gene. The antibody can be applied in Solid tumors, Colorectal Cancer (CRC) Cancers (CRC) Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001118887.2; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285; 7422
UniProt ID O15123; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ14309MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14102MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aNGF75
GTTS-WQ7343MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FPA-150
GTTS-WQ13538MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRX-003
GTTS-WQ14542MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SAR156597
GTTS-WQ5252MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CB-6
GTTS-WQ15125MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SYD985
GTTS-WQ8166MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HL036337
GTTS-WQ14234MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RG-6107
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW